Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
MENLO PARK, Calif., April 17, 2017 -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, announced today that the Company’s presentation time at the Alliance for Regenerative Medicine’s 5th Annual Cell & Gene Therapy Investor Day has been changed. Amber Salzman, Ph.D., president and chief executive officer, will now present at 4:15 pm EDT.
| Event: | Alliance for Regenerative Medicine’s Cell & Gene Therapy Investor Day | |
| Date: | April 27, 2017 | |
| Time: | 4:15 pm EDT | |
| Location: | Boston, MA | |
A live and replay video webcast of the presentation will be available at http://www.arminvestorday.com/webcast.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that can offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat wet age-related macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Contacts for Adverum: Leone Patterson Chief Financial Officer Adverum Biotechnologies, Inc. 650-665-7222 [email protected] Jill Steier Senior Vice President The Trout Group LLC 646-378-2946 [email protected]
